Univariate and multivariate analyses were conducted on data collected from the records of 619 patients with metastatic breast cancer in whom an Adriamycin-containing chemotherapeutic regimen was used. Using a forward, stepwise logistic regression procedure, several models or equations in which a small number of pretreatment factors were incorporated were generated and the probability of response to therapy was accurately predicted. The predictive ability of these models was tested retrospectively in 546 of the 619 patients from whom the data were derived and prospectively in a new population of 200 patients with metastatic breast cancer also treated with a therapeutically equivalent Adriamycin combination. Using similar univariate techniques, pretreatment COMBINATION chemotherapy is the most effective modality of treatment for the majority of patients with metastatic breast cancer.' Overall response rates of 50%-80% have been reported consistently over the last several years, and the duration of survival after chemotherapy has averaged 18 to 24 months. Since the ultimate prognosis of patients with metastatic breast cancer depends on the extent of their response to therapy, the ability to predict response will help to determine the type of treatment that will most likely benefit the patient and will permit accurate assessment of overall prognosis. This capability would lead to the identification of prognostic subgroups, making possible more accurate evaluation and comparison of new treatment modalities. The ability to distinguish poor prognostic groups would permit assessment of new approaches to therapy in these patients. Recently we reported the preliminary results of an analysis of prognostic factors in 619 patients with metastatic breast carcinoma, 2 and found that many pretreatment characteristics correlated with response to therapy and many with length of survival. However, in this analysis we considered all prognostic factors individually. As an extension of these observations, we undertook a multivariate analysis of these factors to determine methods to identify prognostic subgroups based on the few most important factors that correlate with response rate and length of survival.
Univariate and multivariate analyses were conducted on data collected from the records of 619 patients with metastatic breast cancer in whom an Adriamycin-containing chemotherapeutic regimen was used. Using a forward, stepwise logistic regression procedure, several models or equations in which a small number of pretreatment factors were incorporated were generated and the probability of response to therapy was accurately predicted. The predictive ability of these models was tested retrospectively in 546 of the 619 patients from whom the data were derived and prospectively in a new population of 200 patients with metastatic breast cancer also treated with a therapeutically equivalent Adriamycin combination. Using similar univariate techniques, pretreatment COMBINATION chemotherapy is the most effective modality of treatment for the majority of patients with metastatic breast cancer.' Overall response rates of 50%-80% have been reported consistently over the last several years, and the duration of survival after chemotherapy has averaged 18 to 24 months. Since the ultimate prognosis of patients with metastatic breast cancer depends on the extent of their response to therapy, the ability to predict response will help to determine the type of treatment that will most likely benefit the patient and will permit accurate assessment of overall prognosis. This capability would lead to the identification of prognostic subgroups, making possible more accurate evaluation and comparison of new treatment modalities. The ability to distinguish poor prognostic groups would permit assessment of new approaches to therapy in these patients. Recently we reported the preliminary results of an analysis of prognostic factors in 619 patients with metastatic breast carcinoma, 2 and found that many pretreatment characteristics correlated with response to therapy and many with length of survival. However, in this analysis we considered all prognostic factors individually. As an extension of these observations, we undertook a multivariate analysis of these factors to determine methods to identify prognostic subgroups based on the few most important factors that correlate with response rate and length of survival. Since analysis of the results obtained in patients treated in accordance with these protocols revealed similar response rates and length of survival, the data were pooled for the assessment of prognostic factors.
MATERIALS AND METHODS

In
To test prospectively the clinical applicability of the regression models generated from the analysis of the initial 619 patients, another 200 patients treated with various modifications of the FAC regimen between July, 1976 and December, 1977 were selected for study. 3 , 4 There were no significant differences in pretreatment characteristics or outcome between this group of 200 patients and the initial 619 patients. Dose modifications were designed to achieve a nadir absolute granulocyte count between 1,000 and 2,000 cells/mm 3 .
4
If primary therapy failed or progression of disease occurred, a variety of phase II or phase I investigational programs, hormonal manipulation, local radiotherapy, or salvage surgery were used. Therefore, FAC is used in the generic sense in this paper to refer to the treatment programs used for all patients studied.
Prognostic Characteristics
The following pretreatment factors were included in the initial analysis: (1) family history of breast cancer; (2) age of patient at the time of first live birth; (3) age at the time chemotherapy was started; (4) race; (5) disease-free interval; (6) menstrual status; (7) performance status (Zubrod); (8) percentage weight loss; (9) stage at time of diagnosis; (10) size of primary tumor; (11) number of involved axillary nodes; (12) type of surgery (excisional biopsy, segmental resection, simple mastectomy, radical mastectomy); (13) extent of prior radiation therapy, determined by the number of the following sites irradiated (chest wall, major lymph node regions, cervical, dorsal, lumbar, and sacral spinal segments, hemipelvis, skull or brain, mediastinum, and extremity); (14) exposure and response to prior hormonal manipulation (definite response, questionable response, no response, or no prior exposure); (15) prior chemotherapy (low dose/short term or high dose/long term); (16) hemoglobin (pretherapy); (17) platelet count; (18) white blood cell count; (19) absolute lymphocyte count; (20) absolute monocyte count; (21) serum lactic dehydrogenase (LDH); (22) alkaline phosphatase; (23) serum glutamic oxaloacetic transaminase (SGOT); (24) total bilirubin; (25) total protein; (26) albumin; (27) calcium; (28) carcinoembryonic antigen; (29) sites of metastatic disease (breast, skin or chest wall, regional lymph node, bone marrow, lung, pleura, liver, mediastinal and/or intraabdominal masses, ascites, and central nervous system lesions); and (30) extent of disease.
To develop a semiquantitative method to assess extent of disease, we defined criteria for all 12 potential metastatic sites being considered. Extent of disease at each site was defined in a weighted five-point scale: 0 = no disease; I = strong suspicion but insufficient information to define; 2 = minimal involvement; 5 = moderate involvement; and 10 = extensive involvement. Total burden of metastatic disease was estimated by totaling the extent codes of all known disease sites. A more detailed description of this method was reported in 1979.2 In addition to these pretreatment characteristics, the median percentage of 777 standard protocol dose administered per cycle and the median frequency of the cycles also were analyzed for each patient.
Criteria for Response
A complete remission (CR) was defined as disappearance of all clinical evidence of active tumor for a minimum period of eight weeks. A partial remission (PR) was defined as a 50% or greater decrease in the sum of products of the largest perpendicular diameters of measurable lesions, provided no lesions increased in size and no new lesions appeared. Stable disease (SD) was defined as no change in tumor dimensions for a minimum of eight weeks. Progressive disease was defined as an unequivocal 25% increase in the size of any measurable lesions or the appearance of new lesions. Patients were removed from the study if progression was detected after at least two courses of FAC or if unacceptable toxicity occurred at any time during treatment. For purposes of this evaluation, only those responses that took place during the FAC phase of therapy were included in the analysis.
Statistical Method
The two major end points in this study were to assess objective response and to determine the length of survival from the initiation of FAC therapy. Differences in response rates between various prognostic subgroups were assessed by the chi-square test. Curves plotted to show the distribution of survival times for groups of patients were calculated by the method of Kaplan and Meier, 5 and estimates of percentiles of these distributions were determined by linear interpolation. Differences between distributions were determined by means of a generalized Wilcoxon6 test for two curves and Breslow's 7 test for more than two curves.
Multivariate Analysis
In the first phase of multivariate analysis, factors related to response rate were evaluated. Variables were considered in the multivariate analysis if there was some evidence of an association with response rate or if other investigators had reported them as being important. In general, variables for which response rates differed at a significance level of < 0.15 were included. Variables known to be clinically related were grouped into one of three categories: history and physical findings, blood chemistry and hematology, and location and extent of metastatic involvement. A forward stepwise logistic regression procedure was used to determine the combination of patient characteristics important in predicting overall and complete response rates. 8 This procedure resulted in an equation that related the probability of remission to a linear function of regression coefficient multiplied by the patient characteristic, as follows:
where pi is the probability of remission for the ith patient. The regression terms were determined in stepwise fashion so that the first patient characteristic selected in the equation was the most important single characteristic in predicting probability of remission, the second characteristic was the second most important (assuming the first one was in the equation), and so on. The selection process at each step was based on comparison of maximized log-likelihoods, and the significance level associated with addition of a variable to the model was based on increase in maximized log-likelihood over the previous step. In general, factors with a significance level < 0.05 were included.
The second part of the multivariate analysis addressed the question of length of survival. To determine patient characteristics related to survival time, a regression model developed by Cox was applied, 9 resulting in the following equation:
where X (t) is the hazard function at time t, ?o (t) is the hazard function when no characteristics are fitted, and b's are the regression coefficients. This model can be fitted regardless of whether all patients have died. Also, the model was fit in stepwise fashion in the same manner as the logistic regression model; hence, an equation was derived that related the hazard ratio at a time (t) to a linear function of regression coefficients and patient characteristics. Since the hazard function represents the risk of death per unit time, components of the equation which act to increase the hazard function predict for decreased survival time.
RESULTS
Of the 619 patients analyzed, CR was achieved in 99 (16%) and PR in 298 (48%), resulting in a combined response rate of 64%. In 166 patients (27%) SD was present, while in 56 (9%) disease progression occurred. The median survival time from initiation of FAC was 91 weeks (21 months). Median survival times for patients with CR, PR, SD, and progressive disease were 33, 24, 16, and three months, respectively, from the initiation of FAC therapy. These differences in survival distribution were statistically significant (p < 0.01). Analysis of results of the various treatment programs used in the 200 patients in the test group revealed an overall remission rate of 67% and a median survival of 22 months, similar to those in the first 619 patients. Table I summarizes pretreatment factors for which there was some evidence of an association with response. Characteristics traditionally con- sidered to be of prognostic value but which in this study could not be correlated with response rate were age, menopausal status, disease-free interval, hormone responsiveness, and site of metastastic involvement. Table 2 shows the separate regression runs for characteristics in three categories: (1) history, (2) blood chemistry and hematology, and (3) sites and extent of metastatic involvement. In 546 of the 619 patients, the values of all major factors used for predicting prognosis were known. Using the information obtained from regression runs on the three categories of variables, another regression analysis was performed which included the most important variables selected from the three subgroups. Coding of variables for modeling procedures, in parentheses, are: weight loss (1 = <5%, 2 = 5%-10%, 3 = > 10%); performance status (1 = 1 or 2, 2 = 3 or 4); prior radiotherapy (1 = -three sites, 2 = > three sites); prior chemotherapy (0 = no, 1 = yes); race (1 = Caucasian, 2 = 779 other); alkaline phosphatase (1 = <85, 2 = 86-170, 3 = 171-350, 4 = >350); hemoglobin (1 = <11 g/100 mL, 2 = >11 g/100 mL); absolute lymphocyte count (1 = <800, 2 = >800); platelets (1 = <200,000, 2 = >200,000); involvement of opposite breast (0 = no, 1 = yes); involvement of lymph nodes (0 = no, 1 = yes); extent of disease (1 = <12, 2 = 13-20, 3 = >20); and number of sites involved (1 = <2, 2 = >2). The first prognostic model obtained from these variables included platelet count, weight loss, nodal metastases, number of metastatic sites, and race as shown in the following equation: In view of the small number of patients with abnormal platelet count (61 patients), a second model was fitted which did not consider platelet count as a potential factor in the model. Notice that if platelet count is eliminated, different factors are fitted into the model; yet the predictive ability of this second model also is excellent. The factors included in both of these models are routinely obtained during a standard history and physical examination including a baseline blood count and chemistry. Table 3 shows the comparison of observed and predicted responses in the initial 546 patients using the two models. Thep values at the bottom show the excellent correlation (goodness of fit).
An even more simple method to predict response to therapy without resorting to regression models is shown in Table 4 . Seven clearly unfavorable factors that correlated highly with poor Table 2 ). The number of these factors found in each of the 546 patients are shown in Table 4 . Response rates were inversely proportional to the number of unfavorable factors present. This latter method was especially useful in identifying patients having the lowest response rate, but it was less accurate in determining those in the intermediate prognostic groups.
To validate the predictive ability of the regression models prospectively, the 200 patients treated with FAC from 1976 to 1977 were analyzed. Factors that correlated significantly to response in the original population of 546 patients were similar in the second population of 200. Table 5 shows the results of applying regression models no. I and no. 2 to these 200 patients. The actual response rate did not differ significantly from the expected value. Model no. 2 fit the data somewhat better than model no. 1; however, the observed response rates in the two extreme (poor 
Survival
A regression model relating survival to pretreatment characteristics was developed in much the same manner as for the response model, using the proportional hazard model of Cox. ' The results of univariate analysis of pretreatment characteristics that were significantly related to length of survival are shown in Table 6 . While many of these factors are the same as those that significantly correlated with response rate, others are different from the remission analysis. Individual characteristics were selected for multivariate analysis if they related significantly to individual survival times (p < 0. 10). As in the response model, because of the large number of factors that significantly correlated with survival, variables related to history and physical findings, laboratory values, and sites of metastatic disease were analyzed using three individual regression models in order to select from them a smaller number of important factors to be employed. Using the information resulting from the regression runs on the three categories of variables, another regression analysis was performed which included the most important variables selected from the three subgroups. Coding of variables for modeling procedures are given in parentheses: race (I Caucasian, 2 = other); prior radiotherapy (1 = none, 2 = 1-3, 3 =->3); disease-free interval (1 = <24 months, 2 = >24 months); age (1 = <40 years, 2 = >40 years); menopausal status (1 = premenopausal, 2 = perimenopausal and postmenopausal); performance status (1 = 1, 2 = 2, 3 = 3 or 4); weight loss (1 = <5%, 2 = 5%-10%, 3 = >10%); hemoglobin (1 = <11 gi100 mL, 2 = />11 g/mL); absolute lymphocyte count (1 = <800, 2 = >800); platelet count (1 = <200,000/mm 3 , 2 = >200,000/mm (1 = <4 g/100 mL, 2 >4.5 g/100 mL); liver metastasis (0 = no, 1 = yes); lung metastasis (0 = no, 1 = yes), soft tissue involvement (0 = no, I = yes); visceral site involvement (0 = no, 1 = yes); number of involved sites (1 = <2, 2 = >2); and extent of disease (1 = :5, 2 = 6-12, 3 = 13-20, 4 = >20).
While some of these variables did not correlate with survival in our univariate analysis, we included them in the final run since other investigators had shown them to be of prognostic value. Patients in whom any of these variables were unknown were excluded from calculation. Complete information was available for 536 patients. A survival model relating risk of death to a set of six pretreatment characteristics is as follows: These variables are listed in the order of selection by the stepwise process. LDH, the first variable selected, provided the best individual fit to survival. Each of the six variables resulted in an increase in maximized log-likelihood which was significant at the 0.01 level (Table 7) .
Hazard ratios associated with favorable and unfavorable values for each characteristic were calculated by assuming that values for the remaining characteristics in the equation were "average."
With the possible exception of LDH, this method indicated little difference in the impact of the various factors on survival prediction. As shown in Table 7 , patients with unfavorable values for each variable were at almost twice the risk of dying as those for whom the values were favorable. This six-factor regression model was used to calculate hazard ratios for each patient in the group of 536 from which the model was derived. Patients were divided into four levels of hazard ratios, and survival distributions were compared (Fig. 1) . Median survivals for the four hazard ratio groups were 172, 104, 83, and 53 weeks, respectively. There was good separation in the survival distribution according to model prediction, suggesting a good fit of the model to the data.
The population of 200 patients used prospectively to test the remission rate model was used also to test the predictive ability of the survival model. Hazard ratios were calculated for each patient, and the patients were grouped on the basis of these predictions to compare survival. These survival distributions are plotted in Fig. 2 . While the follow-up of this latter patient population was shorter than that of the original group, there was good separation among the four curves during the time period of the study. Estimated median survival times were 137, 114, 62, and 52 weeks for the four hazard ratio groupings considered. These results indicate that the model was effective in categorizing patients according to length of survival. Factors correlated with length of survival in univariate analysis, such as estrogen-receptor status and response to prior hormonal manipulation, were not included in the multivariate analysis models because for most patients this information was not available.' 0 DISCUSSION A large number of clinical factors may influence or correlate with prognosis in breast cancer patients. It is not practical to base clinical decisions on such a large number of variables, and methods of univariate analysis cannot be used to assess the relative prognostic value of each factor. Even univariate analyses reveal a large number of associations between factors without providing a practical method to correct for such associations. In addition, factor interactions are difficult to determine by these methods of analysis. Multivariate analysis, on the other hand, is an effective method of ranking the various prognostic factors in order of predictive ability. In the process, the number of factors that contribute to its prediction of outcome is reduced to a minimum (three to six in our study), eliminating the need for extensive data collection and analysis. This report demonstrates that models such as those described in this paper can predict with fair accuracy an objective response following chemotherapy as well as the length of survival for individual patients. Since predicted outcomes corresponded well with observed outcomes when the models were applied retrospectively and prospectively, the validity of these models was clearly confirmed. Whether these models can be used with any and all combination chemotherapy programs remains to be established. The prePrediction of Survival-Test Poculetion treatment factors considered for analysis in this study are those obtained and documented during an appropriate history and physical examination and the routine laboratory tests obtained for the complete evaluation of a patient with metastatic breast carcinoma.
Results of our univariate analysis confirmed the importance of some factors (performance status, disease-free interval) heretofore considered to be of prognostic value while disproving others which, in this study, did not correlate with prognosis (age, menstrual status, site of metastatic involvement). Nevertheless, we included some of these latter factors in the multivariate analysis since they were of prognostic value in the experience of other investigators. Their failure to be included in the models just confirms their lack of predictive value. New factors of value in assessing prognosis in the univariate analysis were: extent of prior chemotherapy and radiotherapy, response to prior endocrine therapy, race, weight loss, extent of disease, and abnormal hematologic and biochemical findings. Some of these entities (disease-free interval, response to endocrine therapy) reflect biologic characteristics of the tumor, while others (hematologic and biochemical tests) show the extent of involvement.
The regression models presented do not account for possible (hidden) interaction between variables; they do, however, select the most important of those factors with overlapping influence on prognosis without necessarily explaining or justifying the biologic reason for such selection. Thus, if several factors have a simpler impact on prognosis, the models select the one with the largest effect on outcome. Consequently, there were several factors of major importance found in univariate analysis that were totally excluded during multivariate evaluation. For instance, previous reports have emphasized the poor prognostic implications of hepatic metastases. I"12 In our study, liver metastasis did not influence prognosis, but abnormal tests (alkaline phosphatase, LDH, SGOT, bilirubin, and albumin) were indicative of an unfavorable outcome. More detailed analysis showed that in most patients liver metastases were associated with multiple areas of tumor involvement. Thus, liver metastases were generally a reflection of overall tumor burden. This latter factor has profound clinical implications." 1 In both our study and that of George and Hoogstraten," the overall response rate and median survival after treatment with FAC were slightly but significantly lower in non-Caucasians than in Caucasians. Whether this represents the influence of racial characteristics or whether the risk of higher overall tumor burden and other poor prognostic criteria is higher in non-Caucasians is not well defined in either study. Both of these studies show a clear correlation with the number of sites (tumor burden) and poor performance status. In a recent study, Valagussa et al" 4 also found that the site of disease did not correlate with outcome unless concomitant visceral and bone and soft tissue metastases were present, in which case it was a reflection of the overall tumor burden and not of sites of organ involvement.
Systematic application of uniform treatment programs to large patient groups should make it possible to evaluate many factors for their potential prognostic value. Hormonal receptors, kinetic parameters, and pretreatment immunocompetence all may contribute important information to the determination of prognosis." Three models for assessing prognosis were evaluated in this study; although each included different factors, their predictions correspond fairly closely to outcome in the test population. When platelet count was omitted from the model for response, a model with several different factors resulted. It is not unreasonable, therefore, that models containing different prognostic factors can provide a good fit to the original data set and have similar predictive capabilities. In selecting an appropriate 785 model, consideration should also be given to the difficulty in obtaining information on the various factors and their clinical relevance. The usefulness of these models should be evaluated periodically and new and potentially valuable factors incorporated into the analysis. New modalities of therapy, if they become models for comparison, also need to be evaluated with the help of these methods.
Our patient population has been treated over the years with a consistent sequence of therapeutic modalities. It is conceivable that for other treatment regimens which offer similar survival results different factors assume leading prognostic importance. Therefore, these models should be tested and validated on the data base of other institutions or groups (regardless of whether they use similar or different therapies) before it is applied by them in future trials.
Similar caveats are applicable to the survival model, emphasizing the need for updated dynamic evaluation.
If the clinical need is to identify patients with a probable poor response to therapy, then the third model (Table 4) containing the number of unfavorable factors present should be adequate. If accurate prediction of individual prognosis is required in all patients, then either of the first two models would be more appropriate. Therefore, the prognostic heterogeneity of patients with breast cancer can now be approached in a rational manner. This ability to identify accurately various subgroups will be of great help in understanding the biology of breast cancer and in designing and analyzing future therapeutic trials.
